New Weight-Loss drug candidate enters early human testing

NCT ID NCT06945419

First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 26 times

Summary

This early-stage study tests a new medicine called LY4086940 in healthy people and those who are overweight or have obesity, with or without type 2 diabetes. The main goal is to check the drug's safety and how the body processes it. About 216 participants will take part in different parts of the study lasting 7 to 15 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CenExel iResearch, LLC

    NOT_YET_RECRUITING

    Decatur, Georgia, 30030, United States

    Contact Phone: •••-•••-••••

    Contact

  • Clinical Pharmacology of Miami

    RECRUITING

    Miami, Florida, 33172, United States

    Contact Phone: •••-•••-••••

    Contact

  • Endeavor Clinical Trials

    RECRUITING

    San Antonio, Texas, 78240, United States

    Contact Phone: •••-•••-••••

    Contact

  • Fortrea Clinical Research Unit

    ACTIVE_NOT_RECRUITING

    Daytona Beach, Florida, 32117, United States

  • Fortrea Clinical Research Unit

    COMPLETED

    Dallas, Texas, 75247, United States

  • Lilly Centre for Clinical Pharmacology

    COMPLETED

    Singapore, 138623, Singapore

Conditions

Explore the condition pages connected to this study.